Objective: To study the safety and efficacy of modified Sijunzi Tang combined with Tongxie Yaofang in treating diarrhea-predominant irritable bowel syndrome(IBS-D). Method: We searched Pubmed

Cochrane Library

Embase

CNKI

CBM

VIP and Wanfang Data through computer for data as at June 16

2015.All of randomized controlled trials(RCTs) of modified Sijunzi Tang combined with Tongxie Yaofang in treating diarrhea-predominant irritable bowel syndrome were searched

and research literatures included in the RCTs were also traced. Two researchers independently conducted the strict quality evaluation and data extraction for the included studies on the basis of the Cochrane system assessor handbook 5.1

and made a Meta-analysis by using RevMan 5.3 software. Result: Totally 9 RCTs involving 811 patients were included into the study. The Meta-analysis results showed that compared with the pure application of western medicine

Sijunzi Tang combined with Tongxie Yaofang can significantly improve the clinical effective rate[OR=3.75

95%CI(2.43

5.78)

P<0.00001]

with statistical significant differences. In the Adverse reactions

one study showed follow-up reports that during the medication treatment

both groups were not allergic or intolerant to the drug

with no obvious side effect. Sensitivity analysis results showed a stable efficacy evaluation

asymmetric 'Funnel Plot' analysis

with the potential publication bias. Conclusion: Modified Sijunzi Tang combined with Tongxie Yaofang in treating diarrhea-predominant irritable bowel syndrome is superior to conventional western medicine therapy

without any severe adverse effect. However

due to the low methodology and quality and small sample size of included RCTs in this study as well as high bias risk

more high-quality multicenter

randomized

double-blind trials with a large sample size are required to further verify the efficacy and safety of modified Sijunzi Tang combined with Tongxie Yaofang in treating diarrhea-predominant irritable bowel syndrome.